Regeneron Pharmaceuticals Inc
NASDAQ: REGN · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-12
Regeneron Pharmaceuticals Inc (REGN) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $23.07M | $27.37M | $-89.09M | $-72.23M | $96.34M | $-141.68M | $-74.61M | $588.60M | $752.43M | $1.33B | $1.49B | $1.31B | $2.20B | $2.43B | $2.62B | $7.08B | $5.01B | $4.59B | $4.42B | $4.98B |
| Capital expenditures | $2.81M | $18.45M | $34.86M | $97.32M | $99.69M | $57.22M | $49.34M | $156.32M | $333.01M | $677.93M | $511.90M | $272.60M | $383.10M | $429.60M | $614.60M | $551.90M | $590.10M | $926.40M | $755.90M | $898.40M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | $28.07M | $32.52M | $31.26M | $39.90M | $56.09M | $94.16M | $198.40M | $307.24M | $459.05M | $559.88M | $507.28M | $427.40M | $464.30M | $432.00M | $601.70M | $725.00M | $885.00M | $982.80M | $993.70M |
| Free cash flow | $20.26M | $8.93M | $-123.94M | $-169.55M | $-3.35M | $-198.90M | $-123.95M | $432.27M | $419.43M | $652.85M | $974.00M | $1.03B | $1.81B | $2.00B | $2.00B | $6.53B | $4.42B | $3.67B | $3.66B | $4.08B |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $294.55M | $547.47M | $500.18M | $358.69M | — | — | — | — | — | $0.00 | $0.00 | $370.30M |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | $-94.50M | $371.04M | $-253.33M | $305.33M | $113.11M | $160.38M | $-273.90M | $277.53M | $655.00M | $150.10M | $577.00M | $690.80M | $221.30M | — | — | — |
Frequently asked questions
What is Regeneron Pharmaceuticals Inc's revenue?
Regeneron Pharmaceuticals Inc's trailing twelve-month revenue is $14.92B, and consensus projects about $22.40B by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is REGN?
In its most recent fiscal year, REGN ran a gross margin of 85.35%, an operating margin of 24.95%, and a net margin of 31.41%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does REGN generate?
REGN produced $4.08B in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is REGN's balance sheet healthy?
REGN holds $3.12B in cash and equivalents against $1.99B in long-term debt, on $31.26B of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.